Transcriptomic profiling of FP tumors revealed that MAPK, Wnt and TGFβ pathway inhibitors are putative therapies for both external and internal FP, which could be targeted simultaneously to reduce tumor burdens (e.g., systemic targeting via oral dosing). The gene discussed is TGFB1; the disease is neoplasm.